SPARC and FOXP3 in Colorectal Cancer
Author Information
Author(s): Chew Angela, Salama Paul, Robbshaw Anneli, Klopcic Borut, Zeps Nikolajs, Platell Cameron, Lawrance Ian C.
Primary Institution: Centre for Inflammatory Bowel Diseases, Fremantle Hospital, Fremantle, Western Australia, Australia
Hypothesis
Are SPARC, FOXP3, CD8, and CD45RO expression levels associated with colorectal cancer stage, disease outcome, and long-term cancer-specific survival in stage II and III CRC?
Conclusion
High SPARC and FOXP3 levels are associated with better disease outcomes in stage II colorectal cancer and may serve as prognostic indicators.
Supporting Evidence
- High SPARC expression correlated with good disease outcome in stage II CRC.
- High FOXP3 levels were associated with better long-term cancer-specific survival.
- SPARC and FOXP3 expression levels were significantly greater in CRC compared to normal colon tissue.
- Patients with a good disease outcome had higher SPARC expression in their primary tumors.
Takeaway
This study found that higher levels of certain proteins in colorectal cancer tissues can help predict how well patients will do after treatment.
Methodology
The study assessed SPARC, FOXP3, CD8, and CD45RO expression in tissue samples from stage II and III colorectal cancer patients using tissue microarrays and statistical modeling.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the selection of archived samples.
Limitations
The study is retrospective and relies on archived tissue samples, which may not represent current treatment practices.
Participant Demographics
Patients diagnosed with stage II and III colorectal cancer between 1990 and 1999.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website